Gossamer Bio Inc. said it could to raise up to $264.5 million in its initial public offering, according to a Securities and Exchange Commission filing late Wednesday. The San Diego-based biotech company said it planned to offer 14.4 million shares at $16 a share with an additional 2.2 million shares for underwriters to cover overallotments, which if used, would value the company at just over $1 billion. Given the partial government shutdown, which is in its 33rd day, the company said it was using “Section 8(a) of the Securities Act” for the registration to become effective automatically. Gossamer listed this among its risks as it created “the potential for a need for us to file a post-effective amendment and distribute an updated prospectus to investors, or a stop order issued preventing use of the registration statement, and a corresponding substantial stock price decline, litigation, reputational harm or other negative results.” Most of the proceeds will be used to finance clinical trials of three of the company’s drug candidates. Gossamer plans to list under the ticker “GOSS” on the Nasdaq. Bank of America Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are listed among the underwriters.